Blog
RSS FeedPosted by Michael Wonder on 07 Feb 2017
Aussie kids given immediate access to life-changing cystic fibrosis drug
7 February 2017 - From 7 February, children aged two to five will have immediate and free access to Kalydeco (ivacaftor) ...
Posted by Michael Wonder on 06 Feb 2017
Cystic fibrosis sufferers to get lifesaving medication for free after government intervention
6 February 2017 - A life changing drug — previously unaffordable for Australia’s littlest cystic fibrosis sufferers costing $300,000 a ...
Posted by Michael Wonder on 05 Feb 2017
Riverina mother to tackle government over PBS' refusal to list cystic fibrosis drug
5 February 2017 - A government decision to keep a revolutionary drug out of the hands of desperate parents has ...
Posted by Michael Wonder on 04 Feb 2017
Drug game-changer for thousands suffering from cystic fibrosis headed for the PBS
5 February 2017 - Australia's youngest cystic fibrosis sufferers will this week get a massive reprieve when the government lists ...
Posted by Michael Wonder on 22 Jan 2017
Cystic fibrosis sufferer Scarlet Fox 1 million dollars away from access to life-changing drug Kalydeco
21 January 2017 - As a two-year-old living with cystic fibrosis, Scarlet Fox is $1 million away from access to ...
Posted by Michael Wonder on 03 Jan 2017
Amicus Therapeutics set for share of Fabry market after NICE approval
3 January 2017 - England and Wales’ cost effectiveness watchdog NICE has given a final recommendation to a new treatment ...
Posted by Michael Wonder on 03 Jan 2017
'Morally bankrupt': Government stalls funding for life-saving cystic fibrosis drug for children
3 January 2017 - Little Anna dances around her room, stealing hearts with playful pouts that break into cheeky grins. ...
Posted by Michael Wonder on 19 Dec 2016
Vertex announces German reimbursement agreement for Orkambi (lumacaftor with ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis in people ages 12 and older with two copies of the F508del mutation
19 December 2016 - Vertex Pharmaceuticals today announced it has reached a pricing and reimbursement agreement for Orkambi (lumacaftor with ...
Posted by Michael Wonder on 14 Dec 2016
Patients call for funding of drugs for rare disorders
13 December 2016 - People with rare health disorders are urging MPs to consider whether extra funding is needed for potentially ...
Posted by Michael Wonder on 20 Oct 2016
Woman in limbo over rare cancer treatment
21 October 2016 - For 23-year-old Olivia Fryer, three weeks could be everything. ...
Posted by Michael Wonder on 18 Oct 2016
NICE publishes evaluation consultation document for for migalastat hydrochloride
18 October 2016 - NICE has published draft guidance on this highly specialised technology. ...
Posted by Michael Wonder on 18 Oct 2016
Rare cancer patients push for better medication access, say current PBS framework is unfair
18 October 2016 - Patients with rare cancers have ramped up calls on the Federal Government to change regulations around ...
Posted by Michael Wonder on 16 Oct 2016
Rare cancer sufferers face long waits, high costs for treatment
16 October 2016 - Lillian Leigh was taking in the view from the train on her way home from work ...
Posted by Michael Wonder on 11 Oct 2016
A comparative study of drug listing recommendations and the decision-making process in Australia, the Netherlands, Sweden, and the UK
11 October 2016 - Drug listing recommendations from health technology assessment agencies often fail to coincide with one another. ...
Posted by Michael Wonder on 22 Sep 2016
NICE to recommend new drug to treat rare inherited bone disorder in children
22 September 2016 - NICE recommends ‘lifeline’ drug for babies and young children, in draft guidance. ...